Welcome to our dedicated page for Applied Therapeutics SEC filings (Ticker: APLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Applied Therapeutics, Inc. (APLT) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into how the clinical-stage biopharmaceutical company reports its financial condition, pipeline progress, capital structure, and material corporate events related to its rare disease programs.
Investors use Forms 10-K and 10-Q to review Applied Therapeutics’ audited and quarterly financial statements, research and development spending, license and collaboration arrangements, and risk factor disclosures tied to its lead drug candidate govorestat (AT-007) and other programs. These reports also describe the company’s focus on CNS rare metabolic diseases, including Classic Galactosemia, CMT-SORD, and PMM2-CDG, and summarize key regulatory designations such as Orphan Drug and Rare Pediatric Disease status.
Form 8-K current reports are especially important for APLT. Recent 8-K filings describe the Agreement and Plan of Merger with Cycle Group Holdings Limited, including the tender offer structure, cash consideration and non-tradeable contingent value rights (CVRs), as well as the board’s recommendation to stockholders. Other 8-Ks cover the initiation of a strategic alternatives review, workforce reductions, at-the-market equity offering agreements, Nasdaq bid price notifications and listing transfers, leadership changes, and quarterly earnings press releases.
Users interested in insider and security-holder activity can also reference ownership-related filings (such as Forms 3, 4, and 5 when available) to understand how directors, officers, and major holders transact in APLT securities around key clinical or corporate milestones.
On Stock Titan, these Applied Therapeutics filings are updated in near real time as they appear on EDGAR. AI-powered tools can help summarize lengthy 10-K and 10-Q reports, highlight material sections of 8-Ks related to the Cycle merger, strategic reviews, or Nasdaq notices, and make it easier to interpret complex capital structure and contingent value right provisions. This allows readers to quickly grasp what each filing means for APLT’s financial position, regulatory path for govorestat, and the status of the proposed acquisition.
Applied Therapeutics, Inc. prospectus supplement discloses risk factors and incorporates recent SEC filings by reference, including annual and quarterly reports and current reports. The company identifies key corporate risks such as regulatory matters, clinical development, intellectual property, competition, financing needs and macroeconomic impacts. The prospectus lists equity and equity-linked instruments outstanding as of June 30, 2025: 7,658,636 stock option shares (weighted-average exercise $1.54), 5,487,394 restricted stock units, 14,350,618 warrant shares (weighted-average exercise $0.78), 6,913,209 shares available under the 2019 Equity Incentive Plan and 1,747,091 shares available under the 2019 Employee Stock Purchase Plan. It references an FDA Complete Response Letter and Warning Letter dated November 27, 2024. The 2022 audited financials by Ernst & Young LLP include an explanatory paragraph noting substantial doubt about the company’s ability to continue as a going concern.
Applied Therapeutics, Inc. disclosed that Nasdaq notified the company its closing bid price had been below the $1.00 minimum for the last 30 consecutive business days, triggering an initial compliance period. Nasdaq has now granted an additional 180-calendar-day extension to regain compliance with the $1.00 bid-price requirement, extending the deadline to February 2, 2026. In connection with the extension, the company’s listing will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 15, 2025. The Extension Notice does not immediately affect the listing, and the company says it will monitor the bid price and consider available options, including a reverse stock split, to attempt to regain compliance. If the bid price reaches at least $1.00 for 10 consecutive business days before the deadline, Nasdaq will confirm compliance; otherwise Nasdaq may initiate delisting procedures and the company could appeal.
Applied Therapeutics, Inc. reported unaudited Q2 2025 financials showing a sharp decline in liquidity and continued operating losses. Cash and cash equivalents totaled $30.4 million at June 30, 2025, down from $79.4 million at December 31, 2024, while total assets fell to $37.3 million from $86.7 million. The company recorded a net loss of $21.3 million for the quarter and $43.2 million for the six months ended June 30, 2025, driven by R&D and G&A expenses. Operating cash used was $49.0 million for the six months.
The company disclosed material events: an FDA Complete Response Letter and Warning Letter related to the govorestat (AT-007) NDA for Classic Galactosemia, ongoing securities and derivative litigation, and management concluded that substantial doubt exists about its ability to continue as a going concern within one year. Offsetting commercial arrangements include a license to Advanz Pharma with an upfront EUR 10.0 million payment and potential future milestones and royalties, and a subsequent July 31, 2025 out-license of AT-001 to Biossil with a $1.0 million upfront payment.
Applied Therapeutics, Inc. filed a current report to disclose that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company furnished this press release as Exhibit 99.1 to the report, meaning it is provided for information purposes rather than being treated as filed under certain liability provisions of the Exchange Act. The report also notes that the cover page inline XBRL data is included as Exhibit 104, and it is signed by Les Funtleyder as Interim Chief Executive Officer and Chief Financial Officer.